Intuitive Surgical (ISRG) › Analysis

Intuitive Surgical (ISRG) slides, bearish medium conviction

Published November 19, 2026 · ISRG chart, levels and live analysis

Intuitive Surgical fell to $416.19 on November 19, 2026, after a series of insider sales and a $450 million legal settlement dented sentiment. The stock now trades below its 40‑week average, with the daily trend echoing the weekly downtrend, and the balance of evidence points to further downside over the next two to six weeks.

Why it matters

Three insider transactions between November 10 and 18 – including sales by EVP Mark Brosius, VP Fredrik Widman and EVP Gary Loeb – signaled that senior management is exiting at prices ranging from $374 to $444 per share. While the trades were executed under Rule 10b5‑1 plans, the volume and timing coincided with a broader outflow from the health‑care sector ETF XLV, which shed roughly $519 million in the week to November 16. The combined effect was a sharp sell‑off in ISRG, pushing the price 13.7 % below its recent peak of $482.1 on November 4.

The move was not solely sector‑driven. ISRG underperformed the S&P 500 over the past five days, falling 5.39 % versus the index’s 3.50 % decline, and lagged XLV by 0.6 % in the same period. Volume was 86.9 % below its 20‑day average, indicating a lack of buying pressure to absorb the sell‑side. The daily trend aligns with the weekly downtrend, reinforcing the bearish bias.

Analysts remain optimistic on the long‑run, with a consensus “buy” and a mean price target of $488.5, roughly 15 % above the current price. However, the target spread is wide – low $324 to high $685 – and the stock sits 14.8 % below the mean target, suggesting that the upside is already priced in by the market. The valuation argument in the bullish commentary focuses on a Zacks Growth Score of A and projected EPS growth of 25 % this year, but those forecasts have not yet translated into price resilience amid the recent setbacks.

In the broader context, the medical‑robotics market is expanding at double‑digit rates, with global abdominal surgical robot sales projected to grow 17.6 % YoY and the overall medical‑robot market expected to rise over 22 % CAGR through 2035. Yet ISRG’s near‑term price action reflects immediate pressures – legal settlement, insider exits, and sector outflows – that outweigh the macro‑level growth narrative.

What the evidence says

Long‑term, the thesis that ISRG will benefit from a booming surgical‑robot market remains intact, but the stock is now in a down phase, trading below its 40‑week average and its 50‑day SMA of $423.09. The weekly trend is down, and the price sits within a swing‑zone where sellers have historically stepped in on rallies.

For the next two to six weeks, the balance of evidence leans negative. The assessment calls for a bearish stance with medium conviction, based on two of four conviction points: the daily trend follows the weekly downtrend, and ISRG is lagging both the S&P 500 (+2.1 % over 50 days) and XLV (‑3.1 % over 50 days). The breakout math supports a downside move, with the first trigger being a daily close below the round $400 level. The stop is set at $420.95, derived from the swing‑zone at $417.12 plus a quarter of the 14‑day ATR ($15.33). Targets are $397.73 (swing‑zone) and $332.02 (52‑week low), the latter offering a 3.2 : 1 reward‑to‑risk ratio. The math meets a 3‑to‑1 ratio, reinforcing the downside case.

The strongest counter‑argument is the bullish growth narrative and the still‑elevated analyst price targets. Even so, the stock’s current price is 14.8 % below the mean target, and the recent insider sales and sector outflows have already priced in much of the upside. These factors keep the conviction at medium rather than high.

Levels that matter

The structure holds above the swing‑zone level of $417.12, where sellers have historically taken control on upward moves. A weekly close above the 50‑day SMA at $423.09 would signal the end of the weekly downtrend and could shift the narrative.

The downside breakout level is a daily close below $400. If that occurs, the math projects a first target at $397.73, a modest reward‑to‑risk of 0.1, and a deeper target at $332.02, offering a 3.2 : 1 reward‑to‑risk. The stop sits at $420.95, calculated from the swing‑zone plus a quarter of the ATR. Because the breakout meets a 3‑to‑1 ratio, the risk‑reward profile is acceptable for a short‑term trade.

What would change the picture

A weekly close above the 50‑day SMA at $423.09 would invalidate the current bearish picture, indicating that the weekly downtrend may be ending. A significant positive development, such as a better‑than‑expected earnings surprise or a new partnership that accelerates the adoption of the da Vinci 5 system, could also shift sentiment.

What to watch

Get a message when the ISRG picture changes — the agent team watches the levels and the news for you.Create a free account

More ISRG analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.